[go: up one dir, main page]

MX2017014111A - Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico. - Google Patents

Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico.

Info

Publication number
MX2017014111A
MX2017014111A MX2017014111A MX2017014111A MX2017014111A MX 2017014111 A MX2017014111 A MX 2017014111A MX 2017014111 A MX2017014111 A MX 2017014111A MX 2017014111 A MX2017014111 A MX 2017014111A MX 2017014111 A MX2017014111 A MX 2017014111A
Authority
MX
Mexico
Prior art keywords
polypeptide
barrier function
intestinal barrier
metabolic status
immune signalling
Prior art date
Application number
MX2017014111A
Other languages
English (en)
Other versions
MX390092B (es
Inventor
Belzer Clara
Meindert De Vos Willem
Daniel CANI Patrice
Original Assignee
Univ Wageningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wageningen filed Critical Univ Wageningen
Publication of MX2017014111A publication Critical patent/MX2017014111A/es
Publication of MX390092B publication Critical patent/MX390092B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se ha encontrado que un polipéptido extracelular derivado de Akkermansia municiphila es capaz de modular y/o promover la función del sistema inmune de la mucosa intestinal y/o mantener y restaurar el estado metabólico y/o aumentar la integridad física de la barrera de la mucosa intestinal en un mamífero. El polipéptido o las células hospedadoras que comprenden dicho polipéptido pueden emplearse para prevenir y/o tratar una variedad de condiciones que se benefician de una mayor integridad física de la barrera de la mucosa intestinal y/o una función mejorada del sistema inmune de la mucosa intestinal y el estado metabólico.
MX2017014111A 2015-05-06 2016-05-04 Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico MX390092B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15166598 2015-05-06
PCT/EP2016/060033 WO2016177797A1 (en) 2015-05-06 2016-05-04 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Publications (2)

Publication Number Publication Date
MX2017014111A true MX2017014111A (es) 2018-02-26
MX390092B MX390092B (es) 2025-03-11

Family

ID=74184294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014111A MX390092B (es) 2015-05-06 2016-05-04 Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico

Country Status (14)

Country Link
US (2) US10738089B2 (es)
EP (1) EP3292135B1 (es)
JP (1) JP6894382B2 (es)
KR (1) KR102736980B1 (es)
CN (1) CN107980043B (es)
AU (2) AU2016257315A1 (es)
DK (1) DK3292135T3 (es)
EA (1) EA201700507A1 (es)
ES (1) ES2934138T3 (es)
HK (1) HK1252412A1 (es)
IL (1) IL255405B (es)
MX (1) MX390092B (es)
PL (1) PL3292135T3 (es)
WO (1) WO2016177797A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3212001A4 (en) 2014-10-31 2018-04-25 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
HK1252412A1 (zh) 2015-05-06 2019-05-24 Wageningen Universiteit 多肽用於作用於免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的用途
BR112018004532B1 (pt) * 2015-09-10 2022-03-15 Université Catholique de Louvain Uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
WO2018165338A2 (en) * 2017-03-07 2018-09-13 uBiome, Inc. Therapeutic & diagnostics compositions targeting toll-like receptors and methods thereof
US20200246488A1 (en) * 2017-07-17 2020-08-06 The Broad Institute, Inc. Compositions and methods for treating inflammatory bowel diseases
CA3073838A1 (en) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
AU2019306649A1 (en) 2018-07-19 2021-02-04 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
KR102340392B1 (ko) * 2018-10-08 2021-12-17 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
KR102197180B1 (ko) * 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
CN110079474B (zh) * 2019-04-12 2022-11-25 沈阳药科大学 一种高密度培养艾克曼嗜黏蛋白菌的方法
WO2020226438A1 (ko) * 2019-05-07 2020-11-12 한국생명공학연구원 염증성 장질환의 예방 또는 치료용 펩타이드
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
KR102520571B1 (ko) * 2019-09-25 2023-04-13 (주)헬스바이옴 암 치료를 위한 절대혐기성 인체 장내미생물 및 이의 용도
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
CN110950937B (zh) * 2019-11-25 2021-05-04 安徽大学 一种改造的艾克曼菌Amuc_1100蛋白及其制备方法和应用
EP4087859A4 (en) * 2020-01-10 2024-02-14 National Taipei University of Technology PEPTIDE INTERACTING WITH THE TOLL 2 RECEPTOR AND COMPOSITION COMPRISING SAME
CN115666627A (zh) * 2020-03-25 2023-01-31 韩国生命工学研究院 源自嗜黏蛋白阿克曼菌的tars或其片段，及其用途
US20210322492A1 (en) * 2020-04-16 2021-10-21 Amucin Oy Ltd Probiotic strains and uses thereof
CN111690044B (zh) * 2020-05-06 2022-03-01 中南大学湘雅二医院 Amuc1100蛋白的用途
KR20230031895A (ko) 2020-07-01 2023-03-07 바게닝겐 유니버시테이트 면역 신호 전달 및/또는 장관 장벽 기능 및/또는 대사 상태 조절용 Amuc-1100 폴리펩타이드 변이체(polypeptide variants)
WO2022098051A1 (ko) * 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
CN113413466B (zh) * 2020-12-15 2022-08-19 和度生物医药(上海)有限公司 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法
CN115364198A (zh) * 2022-08-23 2022-11-22 广州康泽医疗科技有限公司 膜蛋白Amuc_1100在促进前脂肪细胞脂解和棕色化中的应用
CN116059254B (zh) * 2023-02-27 2025-04-18 广州知易生物科技有限公司 嗜黏蛋白阿克曼氏菌在制备用于改善和治疗多发性硬化症药物中的应用
KR102835266B1 (ko) 2023-09-11 2025-07-17 충남대학교산학협력단 아커만시아 뮤시니필라 m3-2 균주 및 이의 용도
CN117304264B (zh) * 2023-11-27 2024-02-06 中国科学院烟台海岸带研究所 一种具有肠屏障保护功能的五肽rp5及其应用
CN118063567B (zh) * 2024-03-03 2025-11-21 吉林大学 一种用于炎性肠病治疗的重组蛋白的制备与应用
CN119874827B (zh) * 2025-03-27 2025-06-13 杭州康源食品科技有限公司 一种具有免疫调节作用的九肽及其制备和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
AU2002233753B2 (en) * 2001-02-28 2007-03-15 National Institute Of Advanced Industrial Science And Technology Drosophilla strain carrying bradeion gene(s) transferred thereinto
WO2004052917A2 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
US20050180962A1 (en) 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
US20050163764A1 (en) 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US7812121B2 (en) 2006-08-31 2010-10-12 Baker Audrey E GLP-2 mimetibodies, polypeptides, compositions, methods and uses
EP2102350A4 (en) 2006-12-18 2012-08-08 Univ St Louis DARMMICROBIOMA AS A BIOMARKER AND THERAPEUTIC OBJECT FOR THE TREATMENT OF ADIPOSITAS OR ADIPOSITASCONDUCTIVE DISEASES
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
BRPI1012849A2 (pt) 2009-05-11 2018-06-19 Nestec Sa lactobacillus johnsonii la1 ncc533 (cncm i-1225) e distúrbios imunes
WO2011137369A1 (en) * 2010-04-29 2011-11-03 The Regents Of The University Of California Production of gamma-aminobutyric acid by recombinant microorganisms
US9104670B2 (en) 2010-07-21 2015-08-11 Apple Inc. Customized search or acquisition of digital media assets
WO2012052868A2 (en) 2010-10-20 2012-04-26 Koninklijke Philips Electronics N.V. Disaggregation apparatus
EP2449891A1 (en) 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
ES2565407T3 (es) 2010-11-05 2016-04-04 Nestec S.A. Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos
BR112014021388A2 (pt) 2012-02-29 2017-07-18 Ethicon Endo Surgery Inc composições de microbiota e métodos rela-cionados às mesmas
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
KR101740893B1 (ko) * 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
HK1252412A1 (zh) 2015-05-06 2019-05-24 Wageningen Universiteit 多肽用於作用於免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的用途
BR112018004532B1 (pt) 2015-09-10 2022-03-15 Université Catholique de Louvain Uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
US11071626B2 (en) 2018-03-16 2021-07-27 W. L. Gore & Associates, Inc. Diametric expansion features for prosthetic valves

Also Published As

Publication number Publication date
US20210147489A1 (en) 2021-05-20
HK1252412A1 (zh) 2019-05-24
KR102736980B1 (ko) 2024-12-02
US20180265554A1 (en) 2018-09-20
MX390092B (es) 2025-03-11
US11466057B2 (en) 2022-10-11
AU2016257315A1 (en) 2017-11-23
AU2020267210A1 (en) 2020-12-17
WO2016177797A1 (en) 2016-11-10
NZ737765A (en) 2024-08-30
IL255405B (en) 2022-01-01
CA2984985A1 (en) 2016-11-10
PL3292135T3 (pl) 2023-01-02
ES2934138T3 (es) 2023-02-17
DK3292135T3 (da) 2022-10-31
CN107980043B (zh) 2021-09-24
AU2020267210B2 (en) 2023-10-12
KR20180011130A (ko) 2018-01-31
EP3292135B1 (en) 2022-09-21
EP3292135A1 (en) 2018-03-14
JP6894382B2 (ja) 2021-06-30
EA201700507A1 (ru) 2018-05-31
CN107980043A (zh) 2018-05-01
JP2018515502A (ja) 2018-06-14
BR112017023751A2 (pt) 2018-07-31
US10738089B2 (en) 2020-08-11
IL255405A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
MX2017014111A (es) Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico.
IL263152B (en) Hardware-based virtualized security isolation
IL260852B (en) Methods, devices and systems for pulmonary delivery of active agents
BR112017005381A2 (pt) composições que compreendem células recombinantes de bacillus e um inseticida.
CL2016000725A1 (es) Metodo para tratamiento de agua de un lago flotante artificial que comprende: aplicar un oxidante al gua; aplica un floculante; activar la operacion de uno o mas dispositivos de succion movil, filtrar el agua succionada y devolver el agua filtrada a dicho lago; y suministrar agua a dicho lago flotante; y sistema.
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
CO2017003975A2 (es) Expositor publicitario
MX2015016356A (es) Localizacion de dispositivo utilizando camara y señal inalambrica.
BR112017005504A2 (pt) composições que compreendem células recombinantes de bacillus e um inseticida.
BR112017005507A2 (pt) composições que compreendem células recombinantes de bacillus e um fungicida.
MX2016011176A (es) Polipeptidos fhbp meningococicos modificados.
BR112017005379A2 (pt) composições que compreendem células recombinantes de bacillus e um fungicida.
AR101024A1 (es) Inhalador de polvo seco y mecanismo para su accionamiento por inhalación
MX2016013631A (es) Celulas huespedes modificadas y usos de las mismas.
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
MX2017004828A (es) Composicion oftalmica que comprende ciclosporina y trehalosa.
BR112016026143A2 (pt) os métodos e composições compreendendo ácido 10-hidroxi-2-decenóico.
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
CL2016002779A1 (es) Composición para el cuidado de la piel
CL2017000178A1 (es) Compuestos para usar en el tratamiento antihelmíntico
MX382116B (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX2017014745A (es) Aplicador de aspersion en linea para aves con aspersores automaticos de activacion veloz.
MX2017002818A (es) Composiciones topicas de pterostilbeno para utilizarse en el tratamiento de la perdida inducida por uv de la funcion de barrera en la piel.
MX2020014151A (es) Celula hospedadora recombinante que expresa actividad de beta-galactosidasa y/o transgalactosidante deficiente en mananasa, celulasa y pectinasa.
EP3445778A4 (en) PEGYLATED BIOACTIVE PEPTIDES AND USES THEREOF